Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

747 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
Viens P, Palangié T, Janvier M, Fabbro M, Roché H, Delozier T, Labat JP, Linassier C, Audhuy B, Feuilhade F, Costa B, Delva R, Cure H, Rousseau F, Guillot A, Mousseau M, Ferrero JM, Bardou VJ, Jacquemier J, Pouillart P. Viens P, et al. Among authors: fabbro m. Br J Cancer. 1999 Oct;81(3):449-56. doi: 10.1038/sj.bjc.6690714. Br J Cancer. 1999. PMID: 10507769 Free PMC article. Clinical Trial.
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.
Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, Caty A, Rossi JF, Viens P, Bergerat JP, Savary J, Négrier S. Escudier B, et al. Among authors: fabbro m. J Clin Oncol. 1999 Jul;17(7):2039-43. doi: 10.1200/JCO.1999.17.7.2039. J Clin Oncol. 1999. PMID: 10561255 Clinical Trial.
High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?
Macquart-Moulin G, Viens P, Palangié T, Bouscary ML, Delozier T, Roché H, Janvier M, Fabbro M, Moatti JP. Macquart-Moulin G, et al. Among authors: fabbro m. J Clin Oncol. 2000 Feb;18(4):754-64. doi: 10.1200/JCO.2000.18.4.754. J Clin Oncol. 2000. PMID: 10673516 Clinical Trial.
Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
Lotz JP, Pautier P, Selle F, Viens P, Fabbro M, Lokiec F, Viret F, Gligorov J, Gosse B, Provent S, Ribrag V, Micléa JM, Dosquet C, Goetschel A, Cailliot C, Lefèvre G, Genève J, Lhommé C; Groupe d' Intensification des traitements des Tumeurs Ovariennes (ITOV Group). Lotz JP, et al. Among authors: fabbro m. Bone Marrow Transplant. 2006 Apr;37(7):669-75. doi: 10.1038/sj.bmt.1705310. Bone Marrow Transplant. 2006. PMID: 16501591 Clinical Trial.
Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study.
Gonçalves A, Delva R, Fabbro M, Gladieff L, Lotz JP, Ferrero JM, Linassier C, Cottu PH, Viens P, Extra JM. Gonçalves A, et al. Among authors: fabbro m. Bone Marrow Transplant. 2006 Apr;37(7):651-9. doi: 10.1038/sj.bmt.1705302. Bone Marrow Transplant. 2006. PMID: 16501596 Clinical Trial.
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E. Schmitt A, et al. Among authors: fabbro m. Clin Cancer Res. 2009 May 15;15(10):3633-9. doi: 10.1158/1078-0432.CCR-09-0017. Epub 2009 Apr 28. Clin Cancer Res. 2009. PMID: 19401344 Clinical Trial.
747 results